Loading
MAJIC-ET found that ruxolitinib was no better than the usual second-line drugs at controlling platelets in ET, although it eased itching and other symptoms.
MAJIC-ET randomised 110 patients with essential thrombocythaemia resistant to or intolerant of hydroxyurea to ruxolitinib or best available therapy (mostly anagrelide or interferon). Complete response at one year, the primary endpoint, did not differ (about 47 percent in each arm), nor did thrombosis, haemorrhage or transformation; ruxolitinib improved some symptom scores (Harrison and colleagues, Blood 2017). Registered as ISRCTN61925716 alongside MAJIC-PV.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Anagrelide, Essential thrombocythaemia (ET) and the tags essential-thrombocythaemia, mpn.
Shares Ruxolitinib, Small-molecule kinase inhibitors and the tag mpn.
Shares Essential thrombocythaemia (ET), Ruxolitinib and the tag mpn.
Shares Essential thrombocythaemia (ET), Ruxolitinib and the tag mpn.
Shares Ruxolitinib, Small-molecule kinase inhibitors and the tag mpn.
Shares Ruxolitinib, Small-molecule kinase inhibitors and the tag mpn.
Shares Essential thrombocythaemia (ET) and the tag mpn.